Cargando…
SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
Abstract: [Background] Dipeptidyl peptidase-4 (DPP-4) is expressed as CD26 on the surface of immune cells including T cells, suggesting that inhibition of DPP-4 may affect the immune system (1). Actually, DPP-4 inhibitor (DPP-4i)-induced polyarthritis and bullous pemphigoid have been reported (2, 3)...
Autores principales: | Sekizaki, Tomonori, Kameda, Hiraku, Cho, Kyu Yong, Akinobu, Nakamura, Takahashi, Kiyohiko, Wada, Norio, Takeuchi, Jun, Nagai, So, Miyoshi, Hideaki, Atsumi, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208892/ http://dx.doi.org/10.1210/jendso/bvaa046.281 |
Ejemplares similares
-
Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
por: Sekizaki, Tomonori, et al.
Publicado: (2021) -
Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor
por: Oba-Yamamoto, Chiho, et al.
Publicado: (2021) -
SAT-282 Hypothalamic Pituitary Adrenal Axis Hyperactivity in Db/db Mice
por: Kameda, Hiraku, et al.
Publicado: (2020) -
MON-483 Familial Dysalbuminemic Hyperthyroxinemia with False Hypercortisolemia
por: Chiba, Koki, et al.
Publicado: (2020) -
MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
por: Ono, Wataru, et al.
Publicado: (2020)